Breast cancer risk - Genes, environment and clinics;Mammakarzinomrisiko - Gene, Umwelt und Klinik

Geburtshilfe und Frauenheilkunde

Volumn 71, Issue 12, 2011, Pages 1056-1066

  Fasching, P A ^a   Ekici, A B ^b   Adamietz, B R ^a   Wachter, D L ^a   Hein, A ^a   Bayer, C M ^a   Haberle L ^a   Loehberg, C R ^a   Jud, S M ^a   Heusinger, K ^a   Rubner M ^a   Rauh, C ^a   Bani, M R ^a   Lux, M P ^a   Schulz Wendtland, R ^a   Hartmann, A ^a   Beckmann, M W ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

BRCA (breast cancer antigen); breast; breast feeding; CAM (Complementary and Alternative medicine); cancer registry; estrogen receptor

Indexed keywords

AROMATASE INHIBITOR; ISOFLAVONE DERIVATIVE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST FEEDING; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CARCINOGENESIS; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; EARLY DIAGNOSIS; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; MAMMOGRAPHY; MEDICAL INFORMATION; NUTRITION; ONCOGENE; POSTMENOPAUSE; PREGNANCY; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOYBEAN; VALIDATION STUDY;

EID: 84655163517     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0031-1280437     Document Type: Article

References (131)

1. Fasching PA, Fehm T, Janni W et al. Breast cancer therapy a state of the art review. Geburtsh Frauenheilk: 2010; 70 875 886
2. Liedtke C, Kiesel L. Basal/triple negative breast cancer. Geburtsh Frauenheilk: 2009; 69 309 315
3. Liedtke C, Wolf MK, Kiesel L. New concepts for targeted systemic therapy in breast cancer. Geburtsh Frauenheilk: 2010; 70 625 633
4. Ruschoff J, Nagelmeier I, Middel P et al. The role of Her-2/neu in the carcinogenesis of breast cancer when and where? Geburtsh Frauenheilk: 2009; 69 711 716
5. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science: 1994; 266 66 71 (Pubitemid 24345325)
6. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature: 1995; 378 789 792 (Pubitemid 26004412)
7. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA: 1997; 278 1242 1250 (Pubitemid 27435611)
8. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat: 1996; 8 8 18 (Pubitemid 26238963)
9. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet: 2003; 72 1117 1130 (Pubitemid 36530000)
10. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet: 1997; 60 1013 1020 (Pubitemid 27194085)
11. Carlson CS, Eberle MA, Kruglyak L et al. Mapping complex disease loci in whole-genome association studies. Nature: 2004; 429 446 452 (Pubitemid 38715138)
12. Cargill M, Altshuler D, Ireland J et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet: 1999; 22 231 238 (Pubitemid 29297248)
13. Thorisson GA, Smith AV, Krishnan L et al. The International HapMap Project web site. Genome Res: 2005; 15 1592 1593 (Pubitemid 41545013)
14. The International HapMap Project The International HapMap Project. Nature: 2003; 426 789 796
15. Sachidanandam R, Weissman D, Schmidt SC et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature: 2001; 409 928 933 (Pubitemid 32165347)
16. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science: 1996; 273 1516 1517 (Pubitemid 26301653)
17. National Institutes of Health Policy for sharing of data obtained in NIH supported or conducted genome-wide association studies (GWAS). Federal Regist: 2007; 72 49290 49297
18. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature: 2007; 447 1087 1093 (Pubitemid 47014426)
19. Ahmed S, Thomas G, Ghoussaini M et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet: 2009; 41 585 590
20. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet: 2008; 40 703 706 (Pubitemid 351748861)
21. Milne RL, Benitez J, Nevanlinna H et al. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst: 2009; 101 1012 1018
22. Milne RL, Goode EL, Garcia-Closas M et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomarkers Prev: 2011; 20 2222 2231
23. Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst: 2006; 98 1382 1396
24. Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet: 2007; 39 352 358 (Pubitemid 46328496)
25. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet: 2002; 360 187 195
26. Lambe M, Hsieh C, Trichopoulos D et al. Transient increase in the risk of breast cancer after giving birth. N Engl J Med: 1994; 331 5 9 (Pubitemid 24195593)
27. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med: 2003; 349 523 534 (Pubitemid 36951364)
28. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Womens Health Initiative Randomized Trial. JAMA: 2003; 289 3243 3253 (Pubitemid 37430077)
29. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet: 2003; 362 419 427
30. Albring C, Baum E, Beckermann MJ et al. Hormone therapy in the peri and postmenopausal women short version of the S3-guideline. Geburtsh Frauenheilk: 2010; 70 R64 R76
31. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med: 2007; 356 1670 1674 (Pubitemid 46631679)
32. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat: 2008; 107 427 430 (Pubitemid 351172118)
33. Chlebowski RT, Anderson GL, Gass M et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA: 2010; 304 1684 1692
34. Kenemans P, Kubista E, Foidart JM et al. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients design and baseline data LIBERATE trial. Breast: 2007; 16 02 S182 S189
35. Kenemans P, Bundred NJ, Foidart JM et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol: 2009; 10 135 146
36. Untch M, Beckmann MW, Emons G et al. The LIBERATE study: hormone replacement therapy with tibolone increases the risk of recurrence and metastases in breast cancer patients. Geburtsh Frauenheilk: 2009; 69 199 201
37. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev: 2006; 15 1159 1169
38. Heusinger K, Loehberg CR, Haeberle L et al. Mammographic density as a risk factor for breast cancer in a German case-control study. Eur J Cancer Prev: 2011; 20 1 8
39. Boyd NF, Guo H, Martin LJ et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med: 2007; 356 227 236 (Pubitemid 46143226)
40. Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol: 1987; 148 1087 1092 (Pubitemid 17083062)
41. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol: 1976; 126 1130 1137
42. Boyd NF, Byng JW, Jong RA et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst: 1995; 87 670 675
43. Gao J, Warren R, Warren-Forward H et al. Reproducibility of visual assessment on mammographic density. Breast Cancer Res Treat: 2008; 108 121 127 (Pubitemid 351623241)
44. Boyd NF, Martin LJ, Yaffe M et al. Mammographic density. Breast Cancer Res: 2009; 11 03 S4
45. Byng JW, Boyd NF, Fishell E et al. The quantitative analysis of mammographic densities. Phys Med Biol: 1994; 39 1629 1638 (Pubitemid 24306719)
46. Ursin G, Astrahan MA, Salane M et al. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev: 1998; 7 43 47 (Pubitemid 28087141)
47. Vachon CM, Kuni CC, Anderson K et al. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control: 2000; 11 653 662 (Pubitemid 30636365)
48. Butler LM, Gold EB, Greendale GA et al. Menstrual and reproductive factors in relation to mammographic density: the Study of Womens Health Across the Nation (SWAN). Breast Cancer Res Treat: 2008; 112 165 174
49. Loehberg CR, Heusinger K, Jud SM et al. Assessment of mammographic density before and after first full-term pregnancy. Eur J Cancer Prev: 2010; 19 405 412
50. Boyd NF, Martin LJ, Bronskill M et al. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst: 2010; 102 1224 1237
51. World Cancer Fund Hrsg. Krebsprvention durch Ernhrung. Forschung, Daten, Begrndungen, Empfehlungen. Potsdam-Rehbrcke Deutsches Institut für Ernhrungsforschung (DIfE): 2003; 1 28
52. Bundesforschungsinstitut für Ernhrung und Lebensmittel Hrsg. Nationale Verzehrsstudie II, Teil 1. Karlsruhe Max Rbner Institut: 2008; 1 143
53. Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer: 2003; 89 519 523 (Pubitemid 37026437)
54. Benson VS, Pirie K, Green J et al. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer: 2008; 99 185 190
55. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev: 2002; 11 02 S94 S100 (Pubitemid 35265868)
56. Bianchini F, Kaaks R, Vainio H. Weight control and physical activity in cancer prevention. Obes Rev: 2002; 3 5 8 (Pubitemid 34827140)
57. Harvie M, Howell A, Vierkant RA et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa womens health study. Cancer Epidemiol Biomarkers Prev: 2005; 14 656 661 (Pubitemid 40489211)
58. Brennan SF, Cantwell MM, Cardwell CR et al. Dietary patterns and breast cancer risk: a systematic review and meta-analysis. Am J Clin Nutr: 2010; 91 1294 1302
59. Cummings SR, Tice JA, Bauer S et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst: 2009; 101 384 398
60. Michels KB, Mohllajee AP, Roset-Bahmanyar E et al. Diet and breast cancer: a review of the prospective observational studies. Cancer: 2007; 109 2712 2749 (Pubitemid 46906454)
61. Yin L, Grandi N, Raum E et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer: 2010; 46 2196 2205
62. Van t Veer P, van Leer EM, Rietdijk A et al. Combination of dietary factors in relation to breast-cancer occurrence. Int J Cancer: 1991; 47 649 653
63. Landa MC, Frago N, Tres A. Diet and the risk of breast cancer in Spain. Eur J Cancer Prev: 1994; 3 313 320 (Pubitemid 24263974)
64. Zaridze D, Lifanova Y, Maximovitch D et al. Diet, alcohol consumption and reproductive factors in a case-control study of breast cancer in Moscow. Int J Cancer: 1991; 48 493 501
65. Negri E, La Vecchia C, Franceschi S et al. Intake of selected micronutrients and the risk of breast cancer. Int J Cancer: 1996; 65 140 144 (Pubitemid 26048911)
66. Adzersen KH, Jess P, Freivogel KW et al. Raw and cooked vegetables, fruits, selected micronutrients, and breast cancer risk: a case-control study in Germany. Nutr Cancer: 2003; 46 131 137 (Pubitemid 37500506)
67. Boyapati SM, Shu XO, Jin F et al. Dietary calcium intake and breast cancer risk among Chinese women in Shanghai. Nutr Cancer: 2003; 46 38 43 (Pubitemid 37163289)
68. Levi F, Pasche C, Lucchini F et al. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer: 2001; 91 260 263 (Pubitemid 32041750)
69. Katsouyanni K, Willett W, Trichopoulos D et al. Risk of breast cancer among Greek women in relation to nutrient intake. Cancer: 1988; 61 181 185 (Pubitemid 18023130)
70. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst: 2006; 98 459 471
71. Wu AH, Yu MC, Tseng CC et al. Epidemiology of soy exposures and breast cancer risk. Br J Cancer: 2008; 98 9 14
72. Milne RL, Gaudet MM, Spurdle AB et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. Breast Cancer Res: 2010; 12 R110
73. Travis RC, Reeves GK, Green J et al. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet: 2010; 375 2143 2151
74. Campa D, Kaaks R, Le Marchand L et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst: 2011; 103 1252 1263
75. Prentice RL. Empirical evaluation of gene and environment interactions: methods and potential. J Natl Cancer Inst: 2011; 103 1209 1210
76. Berry DA, Iversen ES jr., Gudbjartsson DF et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol: 2002; 20 2701 2712 (Pubitemid 34575644)
77. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet: 1998; 62 145 158 (Pubitemid 28093844)
78. Parmigiani G. BRCAPRO. http://astor.som.jhmi.edu/BayesMendel/brcapro.html Stand: 1.11.2011
79. Antoniou AC, Cunningham AP, Peto J et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer: 2008; 98 1457 1466 (Pubitemid 351543573)
80. Antoniou AC, Pharoah PP, Smith P et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer: 2004; 91 1580 1590 (Pubitemid 39486366)
81. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med: 2004; 23 1111 1130 (Pubitemid 38477070)
82. Antoniou A. BOADICEA. http://www.srl.cam.ac.uk/genepi/boadicea/boadicea- home.html Stand: 1.11.2011
83. National Institutes of Health Breast cancer risk assessment tool. http://www.cancer.gov/bcrisktool/ Stand: 1.11.2011
84. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst: 1994; 86 573 575
85. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat: 1993; 28 115 120 (Pubitemid 24056083)
86. Tice JA, Cummings SR, Smith-Bindman R et al. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med: 2008; 148 337 347 (Pubitemid 351665464)
87. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol: 2011; 22 01 i11 i17
88. Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med: 2010; 362 986 993
89. Azzato EM, Tyrer J, Fasching PA et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst: 2010; 102 650 662
90. Antoniou AC, Wang X, Fredericksen ZS et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet: 2010; 42 885 892
91. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst: 2011; 103 250 263
92. Broeks A, Schmidt MK, Sherman ME et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet: 2011; 20 3289 3303
93. Stevens KN, Vachon CM, Lee AM et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res: 2011; 71 6240 6249
94. Kaufmann M, Rody A. Breast cancer: reduced mortality by early detection and adjuvant therapy. Geburtsh Frauenheilk: 2009; 69 218 232
95. Katalinic A. Breast cancer: declining mortality despite its increasing incidence. Geburtsh Frauenheilk: 2009; 69 237 239
96. Wunderlich P, Plodeck V, Kast K et al. Intensified screening program for women with hereditary predisposition to develop breast cancer our study results and current knowledge in the literature. Geburtsh Frauenheilk: 2009; 69 623 630
97. Kast K, Distler W, Schmutzler R. Current recommendations for the prevention and treatment of hereditary breast cancer. Geburtsh Frauenheilk: 2010; 70 634 639
98. Pfandzelter R, Wulfing U, Boedeker B et al. Diagnostic image quality of mammograms in German outpatient medical care. Geburtsh Frauenheilk: 2010; 70 998 1005
99. Lange J, Leidinger P, Oehler T et al. miRNA biomarkers from blood a promising approach for minimally invasive diagnostic testing. Geburtsh Frauenheilk: 2010; 70 137 141
100. Hauth EA, Wostmann A, Heindel W. Diagnostic imaging of invasive lobular breast carcinoma. Geburtsh Frauenheilk: 2009; 69 836 841
101. Kojima Y, Tsunoda H. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer: 2011; 18 146 151
102. Choi YJ, Seong MH, Choi SH et al. Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers. J Breast Cancer: 2011; 14 119 123
103. Meijers-Heijboer H, van Geel B, van Putten WL et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med: 2001; 345 159 164 (Pubitemid 32662123)
104. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol: 2003; 21 1675 1681 (Pubitemid 46638577)
105. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst: 2001; 93 1633 1637 (Pubitemid 33094870)
106. Hartmann LC, Schaid DJ, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med: 1999; 340 77 84 (Pubitemid 29054841)
107. Hughes KS, Papa MZ, Whitney T et al. Prophylactic mastectomy and inherited predisposition to breast carcinoma. Cancer: 1999; 86 2502 2516 (Pubitemid 30007533)
108. Fasching PA, von Minckwitz G, Fischer T et al. The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. Breast Cancer Res Treat: 2007; 101 95 104 (Pubitemid 47555333)
109. Loehberg CR, Jud SM, Haeberle L et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res Treat: 2010; 121 101 110
110. Distler W, Canzler U, Duffy SR et al. Undesirable gynaecological and operative interventions during treatment of breast cancer with anastrozole and tamoxifen. Geburtsh Frauenheilk: 2010; 70 57 61
111. Goss PE, Ingle JN, Ales-Martinez JE et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med: 2011; 364 2381 2391
112. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther: 2008; 8 1377 1385
113. Antoniou AC, Sinilnikova OM, Simard J et al. RAD51 135G>C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet: 2007; 81 1186 1200 (Pubitemid 350211449)
114. Engel C, Versmold B, Wappenschmidt B et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev: 2010; 19 2859 2868
115. Antoniou AC, Spurdle AB, Sinilnikova OM et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet: 2008; 82 937 948
116. Antoniou AC, Sinilnikova OM, McGuffog L et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet: 2009; 18 4442 4456
117. Antoniou AC, Kartsonaki C, Sinilnikova OM et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet: 2011; 20 3304 3321
118. Spiegelman D, Colditz GA, Hunter D et al. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst: 1994; 86 600 607 (Pubitemid 24143169)
119. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med: 1985; 312 146 151 (Pubitemid 15192861)
120. Pike MC, Siiteri PK, Welsch CW et al. The Epidemiology of Breast Cancer as it relates to Menarche, Pregnancy, and Menopause. Cold Spring Harbor Cold Spring Harbor Laboratory: 1981; 3 21
121. Brinton LA, Schairer C, Hoover RN et al. Menstrual factors and risk of breast cancer. Cancer Invest: 1988; 6 245 254
122. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev: 1993; 15 36 47 (Pubitemid 23269069)
123. Saftlas AF, Hoover RN, Brinton LA et al. Mammographic densities and risk of breast cancer. Cancer: 1991; 67 2833 2838
124. Byrne C, Schairer C, Wolfe J et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst: 1995; 87 1622 1629
125. van Gils CH, Hendriks JH, Otten JD et al. Parity and mammographic breast density in relation to breast cancer risk: indication of interaction. Eur J Cancer Prev: 2000; 9 105 111 (Pubitemid 30337364)
126. Thomas DB, Carter RA, Bush WH jr. et al. Risk of subsequent breast cancer in relation to characteristics of screening mammograms from women less than 50 years of age. Cancer Epidemiol Biomarkers Prev: 2002; 11 565 571 (Pubitemid 34615164)
127. Torres-Mejia G, De Stavola B, Allen DS et al. Mammographic features and subsequent risk of breast cancer: a comparison of qualitative and quantitative evaluations in the Guernsey prospective studies. Cancer Epidemiol Biomarkers Prev: 2005; 14 1052 1059 (Pubitemid 40656447)
128. Nagata C, Matsubara T, Fujita H et al. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer: 2005; 92 2102 2106 (Pubitemid 40966243)
129. Maskarinec G, Pagano I, Lurie G et al. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev: 2006; 15 732 739
130. Kotsuma Y, Tamaki Y, Nishimura T et al. Quantitative assessment of mammographic density and breast cancer risk for Japanese women. Breast: 2008; 17 27 35 (Pubitemid 351228781)
131. Wong CS, Lim GH, Gao F et al. Mammographic density and its interaction with other breast cancer risk factors in an Asian population. Br J Cancer: 2011; 104 871 874